Nykredit A/S’s Dianthus Therapeutics DNTH Stock Holding History

Nykredit A/S’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$147K	Buy	+1,505	New	+$131K	﹤0.01%	1162

Other funds holding DNTH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Nykredit A/S's DNTH Position: Q2 2026 in Review

Nykredit A/S opened a new position in Dianthus Therapeutics (DNTH) in Q2 2026: 1,505 shares worth $147K. The stake represents ﹤0.01% of the portfolio and ranks #1162 among its holdings.

160 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

Nykredit A/S held 1,505 shares of Dianthus Therapeutics worth $147K as of Q2 2026.
Dianthus Therapeutics was a new Nykredit A/S position in Q2 2026.
Dianthus Therapeutics made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1162 holding.
160 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.